NAGIOS: RODERIC FUNCIONANDO

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

dc.contributor.author	Pérez-Breva, Lina	es_ES
dc.contributor.author	Villanueva, Rafael J	es_ES
dc.contributor.author	Villanueva-Oller, Javier	es_ES
dc.contributor.author	Acedo, Luis	es_ES
dc.contributor.author	Santonja, Francisco	es_ES
dc.contributor.author	Moraño, José A	es_ES
dc.contributor.author	Abad, Raquel	es_ES
dc.contributor.author	Vázquez, Julio A	es_ES
dc.contributor.author	Díez Domingo, Javier	es_ES
dc.date.accessioned	2015-06-18T07:05:51Z
dc.date.available	2015-06-18T07:05:51Z
dc.date.issued	2014
dc.identifier.citation	BMC Infectious Diseases Vol. 14 pp. 280-280	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44431
dc.description.abstract	BackgroundMeningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve maximum seroprotection in these groups.MethodsA recent study has provided detailed age-structured information on the seroprotection levels against MenC in Valencia (Spain), where vaccination is routinely scheduled at 2 months and 6 months, with a booster dose at 18 months of age. A complementary catch-up campaign was also carried out in n for children from 12 months to 19 years of age. Statistical analyses of these data have provided an accurate picture on the evolution of seroprotection in the last few years.ResultsAn agent-based model has been developed to study the future evolution of the seroprotection histogram. We have shown that the optimum strategy for achieving high protection levels in all infants, toddlers and adolescents is a change to a 2 months, 12 months and 12 years of age vaccination pattern. If the new schedule were implemented in January 2014, high-risk subjects between 15-19 years of age would have very low seroprotection for the next 6 years, thereby threatening the program.ConclusionsHigh protection levels and a low incidence of meningococcal C disease can be achieved in the future by means of a cost-free change in vaccination program. However, we recommend a new catch-up program simultaneous to the change in regular vaccination program.	es_ES
dc.subject	Meningococcal C conjugate vaccines	es_ES
dc.subject	Seroprotection study	es_ES
dc.subject	Agent-based modelling	es_ES
dc.subject	Vaccination programs	es_ES
dc.title	Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.1186/1471-2334-14-280	es_ES
dc.identifier.idgrec	102901	es_ES